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Background: Over the years, the N-glycosylation of both human and bovine lactoferrin (LF) has been studied exten-
sively, however not all aspects have been studied in asmuch detail. Typically, the bovine LF complex-typeN-glycans
include certain epitopes, not found in human LF N-glycans, i.e. Gal(α1-3)Gal(β1-4)GlcNAc (αGal), GalNAc(β1-4)
GlcNAc (LacdiNAc), and N-glycolylneuraminic acid (Neu5Gc). The combined presence of complex-type N-glycans,
with αGal, LacdiNAc, LacNAc [Gal(β1-4)GlcNAc], Neu5Ac (N-acetylneuraminic acid), and Neu5Gc epitopes, and
oligomannose-type N-glycans complicates the high-throughput analysis of such N-glycoproﬁles highly.
Methods: For the structural analysis of enzymatically releasedN-glycan pools, containing both LacNAc and LacdiNAc
epitopes, a prefractionation protocol based on Wisteria ﬂoribunda agglutinin afﬁnity chromatography was devel-
oped. The sub pools were analysed by MALDI-TOF-MS and HPLC-FD proﬁling, including sequential exoglycosidase
treatments.
Results: This protocol separates the N-glycan pool into three sub pools, with (1) free of LacdiNAc epitopes, (2) con-
taining LacdiNAc epitopes, partially shielded by sialic acid, and (3) containing LacdiNAc epitopes, without shielding
by sialic acid. Structural analysis by MALDI-TOF-MS and HPLC-FD showed a complex pattern of oligomannose-,
hybrid-, and complex-type di-antennary structures, both with, and without LacdiNAc, αGal and sialic acid.
Conclusions:Applying the approach to bovine LF has led to a more detailed N-glycome pattern, including LacdiNAc,
αGal, and Neu5Gc epitopes, than was shown in previous studies.
General signiﬁcance: Bovinemilk proteins contain glycosylation patterns that are absent in humanmilk proteins;
particularly, the LacdiNAc epitope is abundant. Analysis of bovine milk serum proteins is therefore excessively
complicated. The presented sub fractionation protocol allows a thorough analysis of the full scope of bovine
milk protein glycosylation. This article is part of a Special Issue entitled Glycoproteomics.© 2012 Elsevier B.V. All rights reserved.1. Introduction
Lactoferrin (LF) is an 80 kDa, single subunit N-glycoprotein with
multiple functions and involved in many processes, such as activation
of the immune system [1–4] and inﬂammatory regulation [5–7], but
also iron absorption in the intestinal tract [8], or in prevention ofserum albumin; DMB, 1,2-dia-
ection; GRAS, generally recog-
n-exchange chromatography;
toferrin; MALDI-TOF-MS, ma-





l rights reserved.reactive oxygen species formation [9], and growth promotion in cer-
tain tissues [10,11]. Furthermore, LF has been shown to have inhibito-
ry effects on tumourigenesis [12,13] and anti-metastatic activity
[14–16]. LFs contain between 1 and 5 potential glycosylation sites,
depending on the species [17–19]. In humanmilk, LF is a highly abun-
dant protein, with 5.3 mg/ml in colostrum and around 1 mg/ml in
later stages of the lactation [20]. Bovine milk contains a signiﬁcantly
lower amount of LF, with 1.5 mg/ml in colostrum and 20–200 μg/ml
in mature milk [21]. There is a sequence homology of 69% between
human and bovine LF, and although their 3D structures can be largely
superimposed [22], there are some structural differences [23,24].
Human LF consists of 691 amino acids and contains 3 potential glyco-
sylation sites at Asn138, Asn479, and Asn624; Asn138 and Asn479 are
occupied with complex-type N-glycans, whereas Asn624 is usually
unoccupied [25,26]. Bovine LF consists of 689 amino acids and has 5
potential glycosylation sites at Asn233, Asn288, Asn368, Asn476,
and Asn545; Asn233, Asn368, Asn467, and Asn545 are always occu-
pied, and Asn288 is occupied for about 30% [18,19,27].
Fig. 1. NP-HPLC proﬁle of 2AB-labelled N-glycans released from bovine LF.
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and having the GRAS (Generally Recognised As Safe) status, has widely
found use as a humanising protein component for infant formulae. Differ-
ences in the glycosylation pattern of human and bovine LF may be a
source of concern, considering several structural epitopes present in the
bovine LF glycans that do not occur commonly in human glycoproteins,
and in particular in the human LF glycans. The Gal(α1-3)Gal epitope
(αGal epitope), absent in human glycoproteins, e.g. human LF, but
found in bovine glycolipids and glycoproteins, e.g. bovine LF, is an immu-
nogenic structure and has been indicated in allergies [28,29], possibly in-
duced by tick bites [28]. A second epitope that is uncommon in human
glycosylation, absent in human LF, but present in bovine LF, is the Gal-
NAc(β1-4)GlcNAc (LacdiNAc) sequence, next to the Gal(β1-4)GlcNAc
(LacNAc) epitope (known human glycoprotein examples are urokinase
[30], lutropin [31], glycodelin [32], human protein C [33], Tamm-
Horsfall glycoprotein [34], and kallidinogenase [35]). Immunogenicity of
this epitope has been shown in parasite infections [36], but not in relation
to food allergies. Finally,N-glycolylneuraminic acid (Neu5Gc), a variant of
N-acetylneuraminic acid (Neu5Ac), is synthesised by hydroxylation of
Neu5Ac at the nucleotide sugar level in all known mammals, except in
humans, where a mutation has inactivated the responsible enzyme [37].
However, dietary Neu5Gc can be taken up and used in human glycosyla-
tions; it has been found in several human tissues at different levels
[38,39].
Glycosylation of bovine lactoferrin was studied previously [40,41],
however, no speciﬁc focus on LacdiNAc epitopeswasmade.More sensi-
tive equipment allows for more detailed analysis, as has been done for
recombinant human lactoferrin, expressed in the milk of transgenic
cows [42]. In this paperweuse lectin-afﬁnity chromatography to isolate
sub pools of N-glycans, released from bovine LF. By reducing the com-
plexity of glycanmixtures, more detailed analysis of minor compounds
is made possible. Using NP-HPLC proﬁling of 2AB-labelled N-glycans, as
well asMALDI-TOF-MS, the lectin-separated sub poolswere analysed in
native form and after sequential exoglycosidase treatments.
2. Materials and methods
2.1. Materials
Commercial bovine LF was provided by FrieslandCampina DOMO
(Amersfoort, The Netherlands). Reference 2AB-labelled N-glycans
were obtained from Ludger Ltd (Oxfordshire, UK).
2.2. Monosaccharide analysis
Duplicate samples of ~1 mgbovine LFwere subjected tomethanolysis
(1.0 Mmethanolic HCl, 24 h, 85 °C) followed by re-N-acetylation and tri-
methylsilylation. The trimethylsilylated (methyl ester)methyl glycosides
were analysed by GLC on an EC-1 column (30 m×0.32 mm; Alltech,
Breda, The Netherlands), using a Chrompack CP9002 gas chromatograph
(Chrompack, Middelburg, The Netherlands; temperature program
140–240 °C, 4 °C/min). Monosaccharide derivative identities were con-
ﬁrmed by GLC-MS analysis on a Shimadzu QP2010 Plus system (Shi-
madzu, 's-Hertogenbosch, The Netherlands), using an EC-1 columnTable 1
GU values of monosaccharide constituents determined from glycan standards in this
study, compared to GU values of N-glycans from Glycobase 2.0.
This study Glycobase 2.0
Core-linked Fuc(α1–6) 0.3–0.5 0.5
Man 0.75–0.95 0.7–0.9
Gal anywhere 0.85–0.95 0.8–0.9
Neu5Ac(α2–3) anywhere ~0.7 ~0.7
Neu5Ac(α2–6) anywhere ~1.2 ~1.15
GlcNAc (non-bisecting) ~0.7 0.6–0.8(30 m×0.25 mm, Grace, Breda, The Netherlands) and the same temper-
ature program [43].
2.3. Sialic acid determination
For HPAEC-PAD analysis, 10 mg bovine LF samples were hydrolysed
with 1.0 ml 0.1 MHCl (1 h, 80 °C). Sampleswere cooled to RT andneutra-
lised with 50 μl 2 M NaOH. Cleaved sialic acid was separated from glyco-
protein by 5 kDa centrifugal ﬁlters (Sartorius Stedim Biotech GmbH,
Goettingen, Germany) and subsequently analysed on an ICS3000 system
(Dionex BV, Amsterdam, The Netherlands), equipped with a CarboPac
PA-1 column (4 mm×250mm) and an ICS3000 EDpulsed amperometric
detector (pulse potentials and durations: E1 +0.1 V, 410 ms; E2−2.0 V,
20 ms; E3 +0.6 V, 10 ms, E4 −0.1 V, 60 ms), using a linear gradient of
30–360 mM NaOAc in 0.1 M NaOH. Quantitations of Neu5Ac and
Neu5Gc were done by reference to Neu5Ac and Neu5Gc calibration
curves, respectively [44].Fig. 2. WAX-HPLC proﬁles of 2AB-labelled N-glycans of bovine LF. A. total N-glycan
pool, B. WFA fraction I (unbound), C. WFA fraction II (intermediate), D. WFA fraction
III (bound). N0, neutral glycans; N1, monocharged glycans; N2, dicharged glycans.
1446 S.S. van Leeuwen et al. / Biochimica et Biophysica Acta 1820 (2012) 1444–1455For analysis by HPLC-FD, 2 mg bovine LF samples were hydrolysed in
200 μl 2 M propionic acid (3 h, 80 °C). After centrifugation, aliquots of
50 μl supernatant were mixed with 50 μl DMB reagent (7 mM 1,2-dia-
mino-4,5-methylenedioxybenzene, 18 mM sodium hydrosulﬁte, and
750 mM β-mercaptoethanol in 1.5 M propionic acid) and left to react inFig. 3. NP-HPLC proﬁles of 2AB-labelled N-glycans of WFA fraction I; A. without exoglycosi
D. β-galactosidase, E. α-fucosidase, F. α-galactosidase, G. β-galactosidase.the dark for 2.5 h at 50 °C. Analyses were performed on a Waters
2690XE Alliance HPLC system (Waters, Etten-Leur, The Netherlands),
equipped with a Waters 474 ﬂuorescence detector (λex 373 nm, λem
448 nm) on a reversed phase Cosmosil 5C18-AR-II column
(4.6 mm×250 mm, Waters, Eschborn, Germany). Elutions were carrieddase treatment, and after sequential treatment with B. α-mannosidase, C. α-sialidase,
1447S.S. van Leeuwen et al. / Biochimica et Biophysica Acta 1820 (2012) 1444–1455out with acetonitrile/methanol/water (9:7:84, v/v/v) as solvent system
at a ﬂow rate of 1 ml/min [45].
2.4. N-glycan release
A sample of 50 mg bovine LF was denatured with 100 μl β-
mercaptoethanol in 1 ml 1% SDS for 1 h at 85 °C, then 100 μl 1 MStructure m/z GU A
a
B






1945.8 7.98/8.06 n d 1
n d 9.96 n d 1
1929.7 7.70 n d 1
1863.7 8.80 8 0
1863.7 8.71 16 0
n d 9.47 n d 7
n d 8.34 n d 2
1783.7 7.30 7 6
1783.7 7.21 0 0
1783.7 7.08 0 0
1701.6 7.91 13 0
1701.6 7.85 3 0
1621.6 6.42 0 0
1621.6 6.32 0 0
1564.6 5.97 0 0
1539.5 7.18 5 0
1539.5 7.05 4 0
1459.5 5.50 0 0
1418.5 5.94 n d 7
1377.5 6.18 5 0
1256.5 5.07 n d 1
1256.5 4.95 n d 1
 
Table 2
Structures observed in WFA fraction I and after sequential exoglycosidase treatments. For e
integrations), MALDI-TOF-MS confirmation was acquired (m/z values are theoretical masse
aExoglycosidase treatments are in sequence: A. Untreated, B. α-mannosidase, C. α-sialidase
bIt should be noted that sialic acids are commonly lost prior to analysis by the MALDI-TOF-
cPrior to treatment with α-mannosidase many of the minor components are not observed,iodoacetamide was added, and the mixture was kept for 30 min at
55 °C in darkness. N-glycans were released enzymatically, using
peptide-N4-(N-acetyl-β-glucosaminyl)asparagine amidase F (PNGaseF)
(EC 3.5.1.52) (Roche Applied Science, Mannheim, Germany). First Noni-
det P40 substitute (Sigma, St. Louis, MO) was added to a ﬁnal concentra-
tion of 1%. Digestions were performed by adding 15 units of enzyme
activity per mg of protein (48 h, 37 °C) in two batches, i.e. 10 U/mgC D E F G
0 0 0 0 0
0 0 0 0 0
1 0 0 0 0
0 0 0 0 0
1 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0





0 0 0 0 0




0 0 0 0
0 1 0 0 0
0 0 0 0 0
0 0 0 0 0
0 15 15 14 15
8 0 0 0 0
0 0 0 0 0
1 0 0 0 0
2 9 9 10 9
ach assigned NP-HPLC peak (percentages for each profile A-G are based on HPLC peak
s, observed values lie within 1.5 m/z range from this value).        
, D. β-galactosidase, E. α-fucosidase, F. α-galactosidase, G. β-galactosidase.
MS detector and are therefore not observed.
due to overlap with the large oligomannose-derived peaks.
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de-N-glycosylated protein on a Carbograph SPE column (300 mg graphi-
tised carbon, Alltech), using 40% aqueous acetonitrile, containing 0.05%
TFA as eluent. Then, the obtained N-glycan pool was treated with CalBio-
sorb beads (CalBiochem, La Jolla, CA), to remove Nonidet P40 and SDS,
and Dowex H+ 50WX8 (Sigma), and passed across a cotton wool plug
to remove solids.
2.5. 2AB labelling of N-glycans
The puriﬁed and lyophilised N-glycan pool was treated with
0.35 M 2-aminobenzamide (2AB, Sigma), 1 M sodium cyanoborohy-
dride in dimethyl sulfoxide/acetic acid (7:3, v/v) for 2 h at 65 °C. La-
belled glycans were puriﬁed by paper chromatography, using acetic
acid-treated QMA paper (Whatman). Excess 2AB was removed by
washing with 8 times 500 μl acetonitrile. Labelled glycans were eluted
with 5 times 500 μl Milli-Q water [46,47].
2.6. Lectin afﬁnity chromatography
The lyophilised, 2AB-labelled N-glycan pool was dissolved in 500 μl
binding buffer (15 mM PBS, 0.15 M NaCl, pH 7.5) and applied to an
agarose-bound Wisteria ﬂoribunda agglutinin (WFA) column (2 ml
bed volume, Vector Laboratories Ltd., Peterborough, UK). After washing
with 5 column volumes binding buffer, the lectin column was eluted
with 5 column volumes binding buffer/acetic acid (pH 5.5), followed
by 5 column volumes 100 mM GalNAc in binding buffer/acetic acid
(pH 5.5). The column was reconstituted with 20 mM Tris·HCl, pH 4.5,
containing 0.5 M NaCl, and stored in 20% EtOH, 80% 20mM Tris·HCl,
pH 5.8, containing 1 M NaCl, 1 mM CaCl2, and 1 mMMnCl2.
2.7. Mass spectrometry
Matrix-assisted laser-desorption ionisation time-of-ﬂight mass spec-
trometry (MALDI-TOF-MS) experiments were performed on an Axima
Performance mass spectrometer (Shimadzu Kratos, Manchester, UK)
equipped with a nitrogen laser (337 nm, 3 ns pulse width). Positive-ion
mode spectra were acquired using the reﬂectron mode and delayed ex-
traction with software controlled delay time optimised for m/z 1500.
The accelerating voltage was 20 kV and the acquisition range was 800–Scheme 1. Overview of bovine lactoferrin N-g4000 Da. 1-μl samples were mixed on the target plate with 1 μl 2,5-dihy-
droxybenzoic acid (10 mg/ml) as matrix in 40% aqueous acetonitrile.
After drying of the droplets, the spots were re-crystallised with ethanol.2.8. Normal phase-HPLC proﬁling
2AB-labelled N-glycan samples were proﬁled on a TSKgel amide-80
column (4.6 mm×150mm, 3 μm particle size; Tosoh Bioscience GmbH,
Stuttgart, Germany) at 40 °C, using a Waters 2690XE Alliance HPLC sys-
tem (Waters, Etten-Leur, The Netherlands), equipped with a Waters
474ﬂuorescence detector (λex 330 nm,λem 420 nm). A 100-min gradient
of 50 mM ammonium formate, pH 4.4, in acetonitrile (25–56%) was used
at a ﬂow rate of 0.8 ml/min, followed by a 3-min gradient to 100% 50 mM
ammonium formate, which was kept for 5 min at 1 ml/min to clean the
column, ﬁnally followed by a gradient to 25% ammonium formate,
which was kept at 0.8 ml/min for 25min to recondition the column.
The column was calibrated with a 2AB-labelled external dextran
ladder and reference N-glycans (Ludger Ltd., Oxfordshire, UK), and
peak retention times of 2AB-labelled N-glycans were expressed in
dextran-ladder-derived glucose units (GU) values. In Table 1 GU values
for monosaccharide residues, as determined from our standards, and
compared to GU values found in Glycobase 2.0 [48], are presented.2.9. Exoglycosidase assays
Digestions were performed overnight at 37 °C in 50 mM sodium
actetate buffer, pH 5.5. The following enzymes were used: Arthrobac-
ter ureafaciens α-sialidase (1 U/100 μl in 10 mM Na3PO4, 0.1% Micr-
O-protect, pH 7, containing 0.25 mg/ml BSA; Roche, Mannheim, Ger-
many), recombinant Streptomyces plicatus β-N-acetylhexosaminidase
(500 U/100 μl; suspension in 50 mM NaCl, 5 mM Na2EDTA, pH 7.5;
New England BioLabs Inc., Ipswich, MA), jack bean α-mannosidase
(65 U/ml in 3.0 M (NH4)2SO4, 0.1 mM zinc acetate, pH 7.5, Sigma), bo-
vine testis β-galactosidase (0.2 U/100 μl in 3.2 M (NH4)2SO4, pH 5.0;
Sigma), green coffee bean α-galactosidase (20 U/100 μl in 3.2 M
(NH4)2SO4, pH 6.0, containing BSA; Sigma), and bovine kidney α-
fucosidase (51 U/100 μl in 3.2 M (NH4)2SO4, 10 mM NaH2PO4,
10 mM sodium citrate, pH 6.0; Sigma). After digestion the enzymes
were removed by 10 kDa cut-off centrifugal ﬁlters (Millipore).lycan structures found in WFA fraction I.
1449S.S. van Leeuwen et al. / Biochimica et Biophysica Acta 1820 (2012) 1444–14552.10. Weak-anion-exchange chromatography
2AB-labelled N-glycans were analysed by weak-anion-exchange
chromatography (WAX) on a DEAE column (Grace Vydac, 4.6 mm ×
100 mm, 30 °C), using a Waters 2690XE Alliance HPLC system,Fig. 4. NP-HPLC proﬁles of 2AB-labelled N-glycans ofWFA fraction II; A. without exoglycosidase
D. α-fucosidase, E. β-galactosidase, F. α-mannosidase.equipped with a Waters 474 ﬂuorescence detector (λex 330 nm, λem
420 nm). Separation of charge classeswas achieved using a linear gradi-
ent of 0–250 mMammonium formate in 20% acetonitrile. Identiﬁcation
of charged species was achieved by reference to a fetuin N-glycan stan-
dard (Ludger Ltd.). Peak areas were used for quantitation.treatment, and after sequential treatmentwith B.α-sialidase, C. β-N-acetylhexosaminidase,
Structure m/z GU A
a
B C D E F
n d
b
9.58 1 0 0 0 0 0
n d 9.34 1 0 0 0 0 0
n d 9.07 8 0 0 0 0 0
n d 8.49 6 0 0 0 0 0
n d 8.41 15 0 0 0 0 0
n d 8.89 2 0 0 0 0 0
n d 8.80 2 0 0 0 0 0
n d 8.54 7 0 0 0 0 0
n d 8.15 6 0 0 0 0 0
n d 8.01 19 0 0 0 0 0
n d 7.93 4 0 0 0 0 0
n d 7.38 18 0 0 0 0 0
n d 7.13 3 0 0 0 0 0
n d 7.05 5 0 0 0 0 0
n d 6.68 5 0 0 0 0 0
1970.7 7.61/7.56 0 5 0 0 0 0
1945.8 8.16 0 1 0 0 0 0
2011.8 7.36 0 8 0 0 0 0
1824.7 7.17/7.10 0 16 0 0 0 0
1783.7 7.04 0 6 0 0 0 0
1865.7 6.92 0 27 0 0 0 0
1621.6 6.83 0 18 0 0 0 0
1662.6 6.08 0 5 0 0 0 0
1580.6 6.67 0 0 6 5 6 0
1621.6 6.49 0 0 7 11 0 0
1621.6 6.37 0 0 9 14 0 0
1564.6 6.21 0 0 3 0 0 0
1418.5 5.76 0 0 16 18 17 0
1605.6 5.98 0 0 8 0 0 0
1459.5 5.55 0 0 31 40 65 66
1256.5 5.03 0 0 9 9 9 23
1093.4 4.23 0 0 0 0 0 11
1767.7 6.89 0 0 5 0 0 0
1767.7 6.81 0 0 4 0 0 0
1662.6 6.02 0 3 0 0 0 0
1459.5 5.56 0 5 0 0 0 0
1767.7 6.83 0 4 0 0 0 0
1742.6 7.48 0 0 2 3 3 0
Table 3
Structures observed in WFA fraction II and after sequential exoglycosidase treatments. For each assigned NP-HPLC peak (per-
centages for each profile A-F are based on peak integrations), MALDI-TOF-MS confirmation was acquired (m/z values are theo-
retical masses, observed values lie within 1.5 m/z range from this value).     
aExoglycosidase treatments are in sequence: A. Untreated, B. α-sialidase, C. β-N-acetylhexosaminidase, D. α-fucosidase, E. β-
galactosidase, F. α-mannosidase.
bIt should be noted that sialic acids are commonly lost prior to analysis by the MALDI-TOF-MS detector and are therefore not observed.
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3.1. Glycan composition
Monosaccharide analysis [43] of bovine LF showed the presence of
Fuc (trace), Man (3.0), Gal (0.4), GalNAc (0.3), GlcNAc (0.7), and
Neu5Ac (0.3). The low relative abundances of Gal and GlcNAc in refer-
ence to Man, standardised at 3.0 units, are in accordance with large
quantities of oligomannose-type structures [40]. Taking into account
that O-glycans are absent [40–42], the presence of GalNAc in approxi-
mately equal amounts as Gal, indicates a signiﬁcant occurrence of Gal-
NAc(β1-4)GlcNAc (LacdiNAc) epitopes. It should be noted that the
Asn-linkedGlcNAc is not cleaved bymethanolysis, resulting in an under-
estimation of GlcNAc. The carbohydrate content of bovine LF was found
to be 6.7+/−0.2%wt. Sialic acid analysis using both HPLC-FD (DMB-la-
belling; two analyses of duplicate samples) [45] and HPAEC-PAD analy-
sis (triple analysis of duplicate samples) [44] revealed that 8.5+/−0.3%
of released sialic acid is Neu5Gc. It should be noted that in a pool of bo-
vine milk serum proteins ~1.9% of sialic acid is Neu5Gc [49].
3.2. N-glycan release
In order to develop analytical procedures with one uniform batch of
N-glycans, considering the ﬁndings of an inter-laboratory study [50,51],
a large quantity of bovine LF (100 mg) was chosen for digestion with
PNGaseF. The released glycans were isolated by Carbograph SPE chro-
matography, and screened by MALDI-TOF-MS (data not shown), show-
ing major peaks at m/z 1257.4, 1419.5, 1582.1, 1743.6, and 1905.8,
corresponding with the sodium adduct masses of Hex5–9HexNAc2. Tak-
ing into account theN-glycan biosynthetic pathways inmammals, these
peaks indicate a major presence of Man5GlcNAc2–Man9GlcNAc2 struc-
tures, respectively. Note that for presentation of glycan structures in
this report the CFG colour format is used in ﬁgures and schemes [52].
3.2.1. NP-HPLC proﬁling of 2AB-labelled N-glycans
NP-HPLC proﬁling of the derivatised N-glycan pool (Fig. 1) showed
major peaks at GU values corresponding with Man5GlcNAc2 (GU
6.18), Man6GlcNAc2 (GU 7.06, 7.18), Man7GlcNAc2 (GU 7.85, 7.91),Scheme 2. Overview of bovine lactoferrin N-gMan8GlcNAc2 (GU 8.71, 8.80), andMan9GlcNAc2 (GU 9.45), respectiv-
ely. To eliminate these compounds in the NP-HPLC proﬁle, the N-
glycan pool was treated twice with jack bean α-mannosidase, where-
by the N,N′-diacetylchitobiose core with a single (β1-4)-linked man-
nose residue attached (GU 2.77) is formed. Integration of the peak at
GU 2.77 in relation to the remaining peaks afterα-mannosidase treat-
ment, shows a relative abundance of ~65% oligomannose-type struc-
tures and ~35% hybrid- and complex-type structures in the N-glycan
pool. This observation is in accordance with the relatively high
amount of mannose found by monosaccharide analysis, as well as
the major MALDI-TOF-MS peaks corresponding with Man5–9GlcNAc2
structures. These ﬁndings ﬁt very well with previous reports on bo-
vine LF, showing the occurrence of mainly oligomannose-type glycans
[41]. However, so far the presence of relatively large amounts of
hybrid-type structures has not been reported.
3.2.2. WAX-HPLC proﬁling of 2AB-labelled N-glycans
Analysis of the charge distribution of the N-glycan pool by weak-
anion-exchange chromatography (Fig. 2A) showed amajority of neutral
glycans (76%), a signiﬁcant amount of di-charged structures (15%), with
a lower amount of mono-charged structures (9%).
3.2.3. WFA-lectin chromatography combined with NP-HPLC and
WAX-HPLC
By using a WFA-agarose column, the N-glycan pool could be sep-
arated into three fractions. The non-binding fraction I was eluted
with binding buffer (PBS/NaCl, pH 7.5), the intermediate fraction II
with binding buffer, calibrated to pH 5.5 with acetic acid, and the
bound fraction III with 100 mM N-acetylgalactosamine in binding
buffer, calibrated to pH 5.5 with acetic acid.
3.2.3.1. WFA fraction I. The NP-HPLC proﬁle of WFA fraction I showed
major peaks corresponding with Man5–9GlcNAc2 (Fig. 3A), together
with some minor peaks. WAX-HPLC analysis (Fig. 2B) revealed a
large peak for neutral glycans (87%), a peak for mono-charged glycans
(3%), and a peak for di-charged glycans (10%). In order to analyse the
non-oligomannose-type glycans, all oligomannose-type structures
were digested with α-mannosidase (Fig. 3B), resulting in one majorlycan structures found in WFA fraction II.
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of hybrid-type structures (~12%), and peaks corresponding with di-
antennary complex-type structures (~18%). For a further unravelling
of the proﬁle, a series of sequential exoglycosidase treatments was
performed. After each exoglycosidase step, a NP-HPLC proﬁle
(Fig. 3C to G) and a MALDI-TOF mass spectrum were recorded. In
Table 2 a survey of the relative surface area data in the changing
NP-HPLC proﬁles is presented. All included structures, found after
each exoglycosidase step, were conﬁrmed by MALDI-TOF-MS. In this
way for each HPLC peak in Fig. 3A and B the exoglycosidase steps
were followed, yielding the information for elucidating the starting
structures.
Using the combined HPLC/exoglycosidase/MS/Glycobase data,
the various N-glycan structures in WFA fraction I were assigned. AFig. 5. NP-HPLC proﬁles of 2AB-labelled N-glycans ofWFA fraction III; A. without exoglycosidase t
D. β-galactosidase, E. α-mannosidase.survey of these glycans, together with a rough quantitation within
this fraction, based on Fig. 3A and B, is presented in Scheme 1. It
has to be noted that many of the structures overlap. Two notable
glycans are the minor compounds containing the Gal(α1-3)Gal epi-
tope, one of which, i.e. structure 11 in Scheme 1, was previously
found as a major component in a ConA-Sepharose intermediate frac-
tion [41]. It should also be noted that the α-mannosidase treatment
at the start of the analysis also degrades all hybrid-type structures
(structures 6–8, Scheme 1), thereby limiting the information on
hybrid-type structures in this fraction. Considering the abundance
of oligomannose-type structures in the N-glycan pool prior to
WFA-lectin separation (~65%) and the amount in fraction I (~
71%), fraction I consists of approximately 91% of the LF N-glycans.
For the location of Gal(α1-3)- and Neu5Ac(α2-6)- residues,reatment, and after sequential treatment with B.α-fucosidase, C. β-N-acetylhexosaminidase,
Structure m/z GU A
a
B C D E
1970.7 7.61/7.56 9 0 0 0 0
2011.8 7.36 15 0 0 0 0
1824.7 7.17/7.10 14 22 0 0 0
1783.7 7.04 5 5 0 0 0
1865.7 6.92 36 52 0 0 0
1621.6 6.83 12 13 0 0 0
1662.6 6.08 2 2 0 0 0
1662.6 6.02 2 2 0 0 0
1459.5 5.56 5 4 0 0 0
1580.6 6.67 0 0 5 5 0
1621.6 6.49 0 0 6 0 0
1621.6 6.37 0 0 16 0 0
1418.5 5.76 0 0 14 15 0
1459.5 5.55 0 0 53 74 75
1256.5 5.03 0 0 6 6 9
1093.4 4.23 0 0 0 0 16
Table 4
Structures observed in WFA fractionS III and after sequential exoglycosidase treatments. For each assigned NP-HPLC peak (percentages for each profile A-E are based on peak in-
tegrations), MALDI-TOF-MS confirmation was acquired (m/z values are theoretical masses, observed values lie within 1.5 m/z range from this value).      
aExoglycosidase treatments are in sequence: A. Untreated, B. α-fucosidase, C. β-N-acetylhexosaminidase, D. β-galactosidase, E. α-mannosidase.
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cosyltransferases were taken into account [41,53–57].
3.2.3.2. WFA fraction II. NP-HPLC analysis of WFA fraction II (Fig. 4A)
revealed a range of peaks between 6.6 and 10.0 GU. The WAX-HPLC
proﬁle (Fig. 2C) showed a trace amount of neutral glycans, a majorityScheme 3. Overview of bovine lactoferrin N-glof mono-charged glycans (~84%), and a minor amount of di-
charged glycans (~16%). In a similar fashion as was done for WFA
fraction I, all HPLC peaks in Fig. 4A were followed in a series of se-
quential exoglycosidase treatments (Table 3). After treatment with
α-sialidase (Fig. 4B) the three major peaks at 7.38, 8.01, and 8.34
GU shifted to 6.34 (ΔGU 1.04), 6.92 (ΔGU 1.09), and 7.10 (ΔGUycan structures found in WFA fraction III.
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linked Neu5Ac residue. Treatment with Streptomyces plicatus β-N-
acetylhexosaminidase the NP-HPLC proﬁle (Fig. 4C) caused again
shifts in all peaks. The peaks at 6.34, 6.92, and 7.10 GU shifted to
5.76 (ΔGU 0.58), 5.55 (ΔGU 1.37), and 6.37 (ΔGU 0.73), corre-
sponding with the loss of one, two and one HexNAc residues, re-
spectively. The enzyme that was selected (Streptomyces plicatus)
has afﬁnity for GlcNAc(β1-3/4/6)- and GalNAc(β1-4)-linked, leav-
ing the (β1-2)-linked GlcNAc residues of hybrid-type and di-
antennary complex-type structures intact. So far, no tri- or tetra-
antennary complex-type structures have been reported for LF
[40–42], nor have we observed any evidence for such structures
in WFA fraction I. In view of this absence, the selected enzyme
will only cleave GalNAc residues in LacdiNAc epitopes. Combining
the NP-HPLC and MALDI-TOF-MS data, collected after each exogly-
cosidase treatment, and taking into account the Glycobase library
data, the structures in WFA fraction II were assigned, and are pre-
sented in Scheme 2. The quantiﬁcation of the assigned compounds
is based on peaks in NP-HPLC. It should be noted that the intensity
of the peaks in NP-HPLC of WFA fraction II, taken up in the same
amount of Milli-Q water after WFA-separation, is much higher
than for fraction III, indicating fraction II is the major WFA-bound
fraction.
3.2.3.3. WFA fraction III. The NP-HPLC proﬁle of WFA fraction III
(Fig. 5A) showed one major peak at 6.95 GU, corresponding with
the GU value found in WFA fraction II for [GalNAcGlcNAc]2-Man3-
GlcNAc2 (m/z 1865.7); its relationship was conﬁrmed by MALDI-
TOF-MS (not shown). WAX-HPLC proﬁling (Fig. 2D) indicated the
presence of only a neutral fraction. In the NP-HPLC proﬁle several
smaller peaks occurred, corresponding with structures containing
a single LacdiNAc epitope, and minor peaks for core fucosylated
structures. In a similar fashion as carried out for WFA fractions I
and II, WFA fraction III (start proﬁle in Fig. 5A) was subjected to
a series of sequential exoglycosidase treatments (Table 4), moni-
tored by NP-HPLC (Fig. 5B–E) and MALDI-TOF-MS. Combining the
HPLC/exoglycosidase/MS data and taking into account the biosyn-
thetic pathways, structures were assigned, and are presented in
Scheme 3. Again, relative abundances of compounds are based on
NP-HPLC proﬁles.
4. Conclusions
Although the N-glycosylation of bovine LF has been studied exten-
sively before [41], not all aspects were studied in as much detail. First,
the report shows a methodology to simplify the analysis of N-glycans
in case that besides LacNAc also LacdiNAc units are present in the
hybrid- and complex-type oligosaccharides. The inclusion of WFA-
lectin afﬁnity chromatography, applied to the released and 2AB-
labelled N-glycans, in the usual analysis protocol based on NP-HPLC/
WAX-HPLC/exoglycosidases/MS, makes a ﬁrst unravelling of complex
glycan mixtures containing both LacNAc and LacdiNAc elements pos-
sible, thereby simplifying the assignment procedures. Well-separated
fractions, containing mixtures of glycans with speciﬁc structural ele-
ments, are obtained, of which the strongly bound fraction contains
structures with the LacdiNAc unit, and the weakly bound fraction
structures with LacdiNAc units shielded by sialic acid. Secondly, pre-
vious studies had not focused on the quantity of Neu5Gc present in
this glycoprotein. In the present report it is shown that bovine LF con-
tained 8.5+/−0.3% Neu5Gc. This is a relatively high amount, com-
pared to bovine milk and whey protein concentrates (~2.6% and
~1.9%, respectively), however, still lower than reported for ewe and
goat milk [49].
In this research a total of 42 N-glycan structures have been
assigned for bovine LF; in previous work on bovine LF, only 26 N-
glycan structures were reported [41]. For recombinant human LF,expressed in bovine milk, 17 N-glycan structures were published
[42]. Structures containing LacdiNAc were observed in all possible
forms, with up to two sialylated LacdiNAc units, and even previously
unreported LacdiNAc-containing hybrid-type structures. The Gal(α1-
3)Gal- epitope was observed in minor amounts in different structures
of the unbound bulk fraction; previously, only a single structure as a
major component in a ConA-Sepharose intermediate fraction was
found [41].Acknowledgements
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